Feature | September 03, 2008| Dave Fornell

An Introduction to Embolic Protection Devices

The use of embolic protection devices (EPD) during percutaneous cardiac procedures has helped reduce the number of complications due to debris being released into the bloodstream and causing blockages in smaller vessels. The devices are designed to capture and remove debris that may be dislodged during procedures.

There are three classes of EPD devices:

1. Distal occlusion devices use a balloon catheter to temporarily block the flow of blood in a vessel while the intervention is performed. Any debris trapped in a stagnant column of blood can be removed through an aspiration catheter prior to the distal occlusion being released. Experts say one disadvantage of distal occlusion is that the end organ is ischemic during the time the device is in use. This means use of these devices requires quick action by the interventional team to complete a procedure in four to six minutes so blood flow can be restored.

2. Distal filters have a small net, referred to as a “basket,” which is supported by an expandable metal. The device allows blood to continue circulating through the pores of the filter. These filters can be used for up to five to 10 minutes, buying additional time for a procedure.

Most devices have filter pore sizes of around 100 microns. In comparison, a white blood cell measures about 25 microns. Devices that use a nitinol metal mesh filter only tend to let bigger particles through, up to about 150 microns in size. Experts say pores smaller than 100 microns can easily become clogged with platelets.

Distal filters also allow for contrast media injection during the procedure for lesion and arterial visualization.
At the beginning of the procedure the filter is constrained inside a delivery sheath, which the physician guides into position past the area of blockage to be treated. Once in place, the constraint is released and the filter pops open into position. If plaque or blood clots are dislodged during the procedure, the filter will catch them to prevent the emboli from traveling downstream, reducing the chance of an event such as a heart attack. At the end of the procedure the filter containing debris is captured in a retrieval sheath and removed from the patient’s body.

The diameter of the catheters used in placement and retrieval of the protection devices are referred to as the product’s profile.

3. Proximal occlusion devices interrupt the flow of blood upstream of the blockage. Proximal occlusion balloons are placed before the lesion is accessed and are the only type of device that allows crossing of the stenosis under protection.
Physicians say the key factors in choosing EPDs are their ability to maintain perfusion, be effective in capturing emboli, a low profile, deliverability, retractibility and the ability to recover all the debris collected.

Visualization of the protection device using imaging techniques is important because the device may not be seated well in the vessel, which could allow debris to flow around it. This may take views from multiple angles to determine proper positioning. Clinicians can also check to make sure the protection device is situated in the right location.

Experts say prolonged use of distal embolic protection devices can be associated with slow-flow or no-flow, particularly with soft, large plaques. Rapid deployment of an EPD and execution of a procedure by an experienced staff is critical to improving patient outcomes, physicians say.

While most EPDs are cleared by the FDA for coronary saphenous vein grafts interventions and carotid artery stenting, doctors frequently use them for off-label percutaneous procedures to protect patients from embolisms.

Related Content

SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
Claret embolic protection, TAVR, cerebral protection

The Claret TAVR embolic protection system as seen in the aortic arch under angiography. The loops contain embolic filters they protect the ostium of vessles leading to the brain.

Feature | Heart Valve Technology| October 16, 2015
October 14, 2015 — Claret Medical, an innovator in cardiovascular cerebral protection, Data presented this week at Tr
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Technology | June 01, 2015
Silk Road Medical Inc. announced the company received U.S. Food & Drug Administration (FDA) 510(k) clearance for...
Watchman, LAA, left atrial appendage

The Watchman LAA occluder being implanted in the left atrial appendage via a delivery catheter through a transseptal puncture.

Feature | Left Atrial Appendage (LAA) Occluders| April 30, 2015 | Dave Fornell
The long awaited U.S. Food and Drug Administration (FDA) approval of the first transcatheter left atrial appendage (LAA...
News | April 20, 2015
Contego Medical announced the completion of a $5.6 million Series B financing round, led by Hatteras Venture Partners....
TriGuard, Keystone, embolic protection, TAVR

The TriGuard embolic protection system prevents debris from valvuloplasty or TAVR valve deployment from traveling to the brain.

Feature | March 19, 2015
March 19, 2015 — An investigational device that deflects debris away from the brain during transcatheter aortic valve...
Overlay Init